- Home
- PHVS vs INVA Comparison
PHVS vs INVA Comparison
Compare PHVS & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- INVA
- Stock Information
- Founded
- PHVS 2015
- INVA 1996
- Country
- PHVS Switzerland
- INVA United States
- Employees
- PHVS N/A
- INVA N/A
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- INVA Biotechnology: Pharmaceutical Preparations
- Sector
- PHVS Health Care
- INVA Health Care
- Exchange
- PHVS Nasdaq
- INVA Nasdaq
- Market Cap
- PHVS 1.3B
- INVA 1.3B
- IPO Year
- PHVS 2021
- INVA 2004
- Fundamental
- Price
- PHVS $24.30
- INVA $19.46
- Analyst Decision
- PHVS Strong Buy
- INVA Strong Buy
- Analyst Count
- PHVS 5
- INVA 4
- Target Price
- PHVS $35.60
- INVA $40.25
- AVG Volume (30 Days)
- PHVS 123.2K
- INVA 672.1K
- Earning Date
- PHVS 11-12-2025
- INVA 11-05-2025
- Dividend Yield
- PHVS N/A
- INVA N/A
- EPS Growth
- PHVS N/A
- INVA N/A
- EPS
- PHVS N/A
- INVA 0.53
- Revenue
- PHVS N/A
- INVA $370,229,000.00
- Revenue This Year
- PHVS N/A
- INVA $8.17
- Revenue Next Year
- PHVS N/A
- INVA $12.06
- P/E Ratio
- PHVS N/A
- INVA $36.38
- Revenue Growth
- PHVS N/A
- INVA 12.02
- 52 Week Low
- PHVS $11.51
- INVA $16.67
- 52 Week High
- PHVS $26.33
- INVA $22.00
- Technical
- Relative Strength Index (RSI)
- PHVS 59.77
- INVA 43.25
- Support Level
- PHVS $23.20
- INVA $19.24
- Resistance Level
- PHVS $24.75
- INVA $19.74
- Average True Range (ATR)
- PHVS 1.29
- INVA 0.45
- MACD
- PHVS 0.07
- INVA -0.14
- Stochastic Oscillator
- PHVS 84.81
- INVA 17.41
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.